Thrivent Financial for Lutherans Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thrivent Financial for Lutherans cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,336 shares of the specialty pharmaceutical company’s stock after selling 283 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Jazz Pharmaceuticals were worth $1,765,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $25,000. Jones Financial Companies Lllp boosted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares in the last quarter. UMB Bank n.a. grew its position in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 176 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $122.92 on Friday. The company has a 50 day simple moving average of $132.30 and a two-hundred day simple moving average of $122.54. The stock has a market cap of $7.47 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 1.04 and a beta of 0.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06.

Analysts Set New Price Targets

Several research firms have issued reports on JAZZ. Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $187.71.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock valued at $4,022,825 over the last 90 days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.